Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Morning Review
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Insider Transactions
    • Transcripts
  • inderesTV
  • Portfolio
  • Forum
  • Premium
  • Femme
  • Nora AI
  • Learn
    • Investing School
    • Q&A
    • Analysis School
  • About Us
    • Our Coverage
    • Team
Log in to your Inderes Free account to see all free content on this page.
Create account

Enzymatica

2.04 SEK

+4.08 %

Less than 1K followers

ENZY

First North Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Valuation
Income statement
Quarter data

Quarter data

Financial statements, revenue, EBIT, valuation metrics, and quarterly estimates for Enzymatica

Q3/24Q4/242024Q1/25Q2/25Q3/25Q4/252025
Revenue12.617.245.612.38.315.018.353.9
EBITDA-6.4-13.7-52.1-18.0-14.9-6.8
EBIT-6.4-13.7-52.1-18.0-14.9-8.2-10.2-51.4
EBIT-%-51.1 %-79.9 %-114.2 %-146.5 %-180.2 %-54.8 %-55.8 %-95.3 %
Profit before taxes-6.9-13.3-53.3-18.2-14.5-8.2-10.9-51.8
Net income-7.3-13.3-53.2-18.0-14.5-8.4-11.0-51.9
Login required

This content is only available for logged in users

Create account
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.